Skip to content
OmniAb
  • About
    • Overview
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antigen Design
    • Antibody Generation
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmniTaur
      • Bispecific Platforms
    • Screening
      • GEM
      • xPloration
    • Antibody Optimization
      • Fc-Silencing Technology
    • Ion Channel and Transporter Technology
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact
OmniAb
  • About
    • Overview
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antigen Design
    • Antibody Generation
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmniTaur
      • Bispecific Platforms
    • Screening
      • GEM
      • xPloration
    • Antibody Optimization
      • Fc-Silencing Technology
    • Ion Channel and Transporter Technology
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact

Partner Pipeline

  • Overview
  • Why Partner with OmniAb?
  • Partner Pipeline
  • Contact Business Development
partner
program
source
area
phase 1
phase 2
phase 3
registration
approved
Gloria Pharmaceuticals
Arcus Biosciences
Gilead
Zimberelimab OmniRat Oncology
CStone Pharmaceuticals
Pfizer
EQRx
Sugemalimab OmniRat Oncology
Janssen Teclistamab OmniRat Oncology
Hanall Biopharma
Immunovant
Harbour BioMed
Batoclimab OmniRat Immunology
Genentech Tiragolumab OmniRat Oncology
Genmab
BioNTech
GEN1046 OmniRat Oncology
Merck KGaA M6223 OmniRat Oncology
Aptevo Therapeutics APVO436 OmniMouse Oncology
Janssen JNJ-70218902 OmniRat Oncology
Janssen JNJ-78306358 OmniRat Oncology
Genmab GEN1047 OmniRat Oncology
CTTQ S095017 OmniRat Oncology
Symphogen by Servier S95018 OmniRat Oncology
Symphogen by Servier S95024 OmniRat Oncology
Symphogen by Servier S95029 OmniRat Oncology
AbbVie ABBV-383 OmniFlic Oncology
Ancora by AstraZeneca TNB-486 OmniFlic Oncology
Amgen AMG 340 OmniFlic Oncology
SalubrisBio SAL003 OmniRat Metabolic
Curon CN1 OmniRat Oncology
Zhilkang Hongyi Undisclosed OmniRat Oncology
Boehringer Ingelheim Undisclosed OmniChicken Undisclosed
Undisclosed Undisclosed OmniRat Undisclosed
Merck KGaA M9140 OmniRat Oncology
Genmab
BioNTech
GEN1053 OmniRat Oncology
Janssen JNJ-79635322 OmniRat Oncology
PartnerGloria Pharmaceuticals
Arcus Biosciences
Gilead
ProgramZimberelimab
SourceOmniRat
AreaOncology
PhaseApproved
PartnerCStone Pharmaceuticals
Pfizer
EQRx
ProgramSugemalimab
SourceOmniRat
AreaOncology
PhaseApproved
PartnerJanssen
ProgramTeclistamab
SourceOmniRat
AreaOncology
PhaseApproved
PartnerHanall Biopharma
Immunovant
Harbour BioMed
ProgramBatoclimab
SourceOmniRat
AreaImmunology
PhasePhase 3
PartnerGenentech
ProgramTiragolumab
SourceOmniRat
AreaOncology
PhasePhase 3
PartnerGenmab
BioNTech
ProgramGEN1046
SourceOmniRat
AreaOncology
PhasePhase 2
PartnerMerck KGaA
ProgramM6223
SourceOmniRat
AreaOncology
PhasePhase 2
PartnerAptevo Therapeutics
ProgramAPVO436
SourceOmniMouse
AreaOncology
PhasePhase 1
PartnerJanssen
ProgramJNJ-70218902
SourceOmniRat
AreaOncology
PhasePhase 1
PartnerJanssen
ProgramJNJ-78306358
SourceOmniRat
AreaOncology
PhasePhase 1
PartnerGenmab
ProgramGEN1047
SourceOmniRat
AreaOncology
PhasePhase 1
PartnerCTTQ
ProgramS095017
SourceOmniRat
AreaOncology
PhasePhase 1
PartnerSymphogen by Servier
ProgramS95018
SourceOmniRat
AreaOncology
PhasePhase 1
PartnerSymphogen by Servier
ProgramS95024
SourceOmniRat
AreaOncology
PhasePhase 1
PartnerSymphogen by Servier
ProgramS95029
SourceOmniRat
AreaOncology
PhasePhase 1
PartnerAbbVie
ProgramABBV-383
SourceOmniFlic
AreaOncology
PhasePhase 1
PartnerAncora by AstraZeneca
ProgramTNB-486
SourceOmniFlic
AreaOncology
PhasePhase 1
PartnerAmgen
ProgramAMG 340
SourceOmniFlic
AreaOncology
PhasePhase 1
PartnerSalubrisBio
ProgramSAL003
SourceOmniRat
AreaMetabolic
PhasePhase 1
PartnerCuron
ProgramCN1
SourceOmniRat
AreaOncology
PhasePhase 1
PartnerZhilkang Hongyi
ProgramUndisclosed
SourceOmniRat
AreaOncology
PhasePhase 1
PartnerBoehringer Ingelheim
ProgramUndisclosed
SourceOmniChicken
AreaUndisclosed
PhasePhase 1
PartnerUndisclosed
ProgramUndisclosed
SourceOmniRat
AreaUndisclosed
PhasePhase 1
PartnerMerck KGaA
ProgramM9140
SourceOmniRat
AreaOncology
PhasePhase 1
PartnerGenmab
BioNTech
ProgramGEN1053
SourceOmniRat
AreaOncology
PhasePhase 1
PartnerJanssen
ProgramJNJ-79635322
SourceOmniRat
AreaOncology
PhasePhase 1

Note: Most advanced status for each program shown.

About

  • Overview
  • Team
  • Board of Directors
  • Careers

Partnerships

  • Overview
  • Why Partner with OmniAb?
  • Partner Pipeline
  • Contact Business Development

Technology

  • Overview
  • Antigen Design
  • Antibody Generation
  • Screening
  • Antibody Optimization
  • Ion Channel and Transporter Technology
  • Scientific Publications

OmniAb, Inc.
5980 Horton Street
Suite 600
Emeryville, CA 94608

[email protected]
[email protected]

Contact | Privacy Policy | Disclaimer

© 2023 OmniAb, Inc. All rights reserved.